A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer

NCT05141357 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Slow Recruitment

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: HBI-8000 in combination with pembrolizumab

Sponsor

HUYABIO International, LLC.